Recent studies, including several in this journal, have revived interest in the catecholamine metabolising enzyme catechol-O-methyltransferase (COMT), and suggest strongly that it is involved in the dopaminergic regulation of the prefrontal cortex (PFC), and its dysfunction in schizophrenia. [1] [2] [3] These effects are mediated, at least in part, by the Val 158 Met polymorphism which influences the activity of the enzyme, and are probably modified by other variables, including the expression of soluble (S-COMT) and membrane-bound (MB-COMT) isoforms. Here, we report an additional and potentially important feature of COMT: the occurrence of two variants of MB-COMT protein in human PFC, and the possibility that they are differentially regulated in schizophrenia and bipolar disorder, and in association with the Val Met polymorphism. 5 COMT protein was quantified using enzyme-linked immunosorbent assay (ELISA), and the relative expression of COMT isoforms was investigated using SDS-PAGE and Western blotting. Proteins were separated on 15% tris-glycine polyacrylamide gels and electrophoresis was continued until clear separation of the 31 kDa and 39 kDa markers of a kaleidoscope prestained marker (Biorad, UK) was observed, to ensure high resolution. Both ELISA and Western blotting used a previously described anti-COMT antibody 6 (Chemicon, UK) that recognises both S-and MB-COMT. Data were analysed with analysis of variance (ANOVA) and LSD post hoc tests. The effects of potential confounders were investigated using Pearson's coefficient and were included as covariates where appropriate.
The ELISAs demonstrated neither group differences nor genotype effects (F's < 1.6), consistent with the lack of change in COMT mRNA reported previously (see Supplementary Tables and Figure) . 5, 7 However, the Western blots revealed an unexpected result. In addition to the two bands anticipated, at approximately 25 kDa (S-COMT) and 32 kDa (MB-COMT), 6 a novel 39 kDa band was also seen ( Figure 1 ). The fact that this band has not been reported before probably reflects the longer time for which we ran the gels, and the higher percentage of gel used (10% is usual), because under other conditions we have found that the doublet merges into one broader band. Putative confirmation that the 39 kDa band is a variant of COMT, most likely of MB-COMT, comes from preliminary mass spectroscopy data which has thus far revealed fragments of COMT sequence (Residues 136-151, 160-179 and 197-211 of MB-COMT; EMT, DRW, S Markey, unpublished observations). We have also found this band present in human lymphocytes (EMT, J Chen, Y Sei and DRW; Figure 1 ), which precludes its being a post mortem artefact. Furthermore, similar bands are seen in the mouse brain and are absent in COMT knockout mice (DRW and J Chen; see Supplementary  Tables and Figure) . We are investigating whether the 39 kDa variant of COMT arises from alternative splicing or from post-translational modification.
The second result of interest came following the quantitation of the MB-COMT bands. While there were no absolute differences in the immunoreactivity of either band between the groups, the relative immunoreactivity of the bands, expressed as the abundance of the 39 kDa band as a proportion of total MB-COMT (represented by the sum of 32 and 39 kDa bands), differed between the diagnostic groups (F 3,51 = 4.7; P < 0.01; see Figure 1 ), being increased in the patients with schizophrenia and bipolar disorder. However, this main effect of diagnosis in bipolar disorder and schizophrenia is complex and appears to be accounted for by different effects across the diagnostic groups. In the schizophrenia group, the increased relative immunoreactivity of the 39 kDa band appears to result from a nonsignificant decrease in immunoreactivity of both the 32 kDa and the 39 kDa bands, which is relatively greater for the 32 kDa band than for the 39 kDa band (i.e. the increased relative 39 kDa band expression results from a decrease in the denominator). In contrast, the bipolar subjects appear to show a nonsignificant increase in 39 kDa band immunoreactivity with little change in 32kDa band expression (i.e. in this group the increased relative 39 kDa band expression results from an increase in the numerator). Thus, the source of the relative change in band expression in schizophrenia and bipolar disorder may come from different sources, although clearly this interpretation should be treated with caution, as it is based on nonsignificant changes.
In addition, there was a trend effect of Val 158 Met genotype on the relative immunoreactivity of the bands (F 2,43 = 3.1; P < 0.1), with a significant difference between the homozygote groups (P < 0.05; Figure 1) ; this later finding has been replicated in a separate, large cohort of normal individuals. 8 This measure was not correlated with antipsychotic exposure, age at death, duration of illness, brain pH or post-mortem interval.
These data suggest that MB-COMT exists in two forms, which may be differentially affected by the Val 158 Met genotype and differentially regulated in psychiatric disorders. Obviously, speculation as to the functional significance of these findings must be curtailed until the molecular identity and origin of the new isoform is established and until confirmatory studies are done. Nevertheless, the results already have several potential implications. First, they suggest that COMT expression is subtly altered in schizophrenia and bipolar disorder, albeit in different ways, despite no change in total mRNA or protein. [5] [6] [7] Second, they provide further indications that COMT may be relevant in bipolar disorder as well as schizophrenia. 9 Finally, these data provide new evidence that the Val 158 Met genotype influences protein expression. 6, 10 As the Val Met polymorphism on the relative stability of the 32 kDa and 39 kDa forms, rather than a specific genotype effect on the 39 kDa band per se. Specifically, this pattern would be anticipated if the 39 kDa band were relatively more resistant to the destabilising presence of the Met 158 residue than the 32 kDa band. 10 While previous work has shown that total COMT activity and MB-COMT immunoreactivity in PFC of the human brain is strongly predicted by COMT Val
158
Met genotype, 6 expression of this isoform may ultimately impact on this effect.
In summary, the finding of a putative new isoform reveals a hitherto unexplored area of COMT biology which may be relevant to its involvement in schizophrenia and bipolar disorder, and potentially to the use of COMT inhibitors in ameliorating their cognitive deficits. 
